Syndesi Therapeutics

Louvain-la-Neuve, March 1, 2022 – VIVES today announced that AbbVie (NYSE: ABBV) has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio. This acquisition gives AbbVie access to Syndesi’s portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer’s disease and major depressive disorder.

There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases,” said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. “With AbbVie’s acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.”

Philippe Durieux, CEO of Sopartec, the management company of VIVES: "The acquisition of Syndesi by Abbvie illustrates our ability of creating bridges between science and industry. After the IPO of iTeos Therapeutics last year, Syndesi represents the second potential unicorn of VIVES Fund. We are extremely pleased with this acquisition knowing that Abbvie is the real ideal partner to further accelerate this novel Alzheimer’s therapeutic approach, an area of large unmet medical needs

The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders.

We have been impressed with the vision of AbbVie’s neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases,” said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. “I am delighted with the closing of this deal. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.


Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

About Syndesi Therapeutics
Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi’s unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission.
Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Syndesi’s Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation – JJDC, Inc., SRIW (Société Régionale d’Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. The company has also benefited from support from the Walloon Region. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018.

About VIVES Inter-University Fund
Established in July 2020, VIVES Inter-University Fund is a multi-sector technology fund that invests in projects with a positive societal and/or environmental impact. It takes over from VIVES I and VIVES II, launched by UCLouvain in 2003 and 2011, which made it possible to invest so far in 27 projects, attracting nearly € 1200M. Key outcomes: iTeos (listed on the Nasdaq), Novadip, Tessares, Axinesis, Botalys, Upstreem, Promethera, Virovet, E-Peas, Aphea, Syndesi, SmartNodes, etc.
VIVES Inter-University Fund is the third fund managed by Sopartec, UCLouvain’s technology transfer and investment company. The first closing of the VIVES IUF fund is capitalized to the level of € 32M with a final target of € 60M. The main investors are Belfin, BNPP Fortis Private Equity, IMBC Spinnova, ING Belgium, Investsud, Namur Invest, Invest BW (Nivelinvest), Finance & Invest.Brussels (SRIB), Sambrinvest, Securex, SFPI-FPIM as well as Sopartec and its management team.
VIVES IUF is involved in spin-offs from UCLouvain or its partner universities, being: KULeuven (BE), University of Paris (FR), University of Wageningen (NL), University of Luxembourg (LU) – as well as in start-ups located within a perimeter of 400 kilometers around Louvain-la-Neuve.



Frank Benenati
(224) 688-4169

Liz Shea
(847) 935-2211
AbbVie Inc. +1 (847) 938-9190
1 North Waukegan Road
North Chicago, IL 60064